Investors should consider voting on the proposals, particularly the equity plan expansion and share authorization increase which could lead to future dilution. Monitor for any insider trading activity around these governance changes.
Price Chart
Executive Summary
Relmada Therapeutics is holding its 2026 annual meeting where shareholders will vote on four key proposals: electing two Class II directors, ratifying the appointment of CBIZ CPAs P.C. as auditors, increasing the number of shares available under its equity incentive plan by 3 million, and increasing its authorized common stock from 150 million to 200 million shares. The filing is a routine proxy statement with no material financial data disclosed.
Key Facts
- Relmada Therapeutics is holding its 2026 annual meeting
- Shareholders will vote to elect two Class II directors: Charles J. Casamento and Sergio Traversa
- Proposal to ratify CBIZ CPAs P.C. as independent auditors for 2026
- Proposal to increase shares available under the 2021 Equity Incentive Plan by 3 million
- Proposal to increase authorized common stock from 150 million to 200 million shares
Financial Impact
3 million additional shares for equity incentives, increase in authorized shares from 150M to 200M
Risk Factors
- Potential dilution from increased share authorization and equity incentives
- Governance risks if shareholder approval is not obtained for key proposals
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001213900-26-045194 |
| Document: 0001213900-26-045194-index-headers.html | 0001213900-26-045194 |
| Document: 0001213900-26-045194-index.html | 0001213900-26-045194 |
| Document: 0001213900-26-045194.txt | 0001213900-26-045194 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | Insider Cluster | $4.52 $4.12 | ▼ −8.85% | ▼ −8.63% | $3.60 (−20.35%) |
May 13, 2026 20w ago | S-3ASR | $7.42 $7.21 | ▲ +2.83% | ▲ +2.11% | $3.60 (+51.48%) |
May 12, 2026 20w ago | 8-K | $7.49 $7.03 | ▼ −6.14% | ▼ −4.98% | $3.60 (−51.94%) |
Apr 17, 2026 23w ago | DEFA14A | $7.37 $7.03 | ▼ −4.61% | ▼ −5.53% | $3.60 (−51.15%) |
Apr 3, 2026 26w ago | S-3 | $6.90 $7.38 | ▲ +6.96% | ▲ +2.82% | $3.60 (−47.83%) |
Mar 19, 2026 28w ago | Press Release | $6.07 $6.43 | ▲ +5.93% | ▲ +8.08% | $3.60 (−40.69%) |
Mar 12, 2026 29w ago | Press Release | $6.15 $6.25 | ▲ +1.63% | ▲ +2.60% | $3.60 (−41.46%) |
Mar 9, 2026 29w ago | Press Release | $7.17 $6.18 | ▼ −13.81% | ▼ −12.45% | $3.60 (−49.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access